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Thank you for your comments about our manuscript and we read with interest the 
remarks made by the two reviewers. In submitting a revised version of this work we 
have tried where possible to address the points raised, and altered the manuscript 
accordingly. 
I would like to thank the reviewers for their constructive comments that I feel have 
helped us improve the manuscript.
I look forward to hearing from you in the near future.
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Dear Professor Caldecott
Manuscript. DNAREP_2019_32
Title: Deciphering the interstrand crosslink DNA repair network expressed by 
Trypanosoma brucei
Thank you for your comments about our manuscript and we read with interest the 
remarks made by the two reviewers. In submitting a revised version of this work we 
have tried where possible to address the points raised, and altered the manuscript 
accordingly. Below we discuss our response to the comments and outline the changes 
made to the manuscript.
1. In relation to XPF and/or ERCC1, we agree that construction and phenotypic analysis 
of the additional T. brucei lines noted by the referee would be of interest. However, 
previous studies have clearly shown that ERCC1 and XPF (as well as other 
components of the NER pathway e.g. XPC, XPE, XPB, XPD) are essential for the 
growth of bloodstream form parasites (Alsford et al 2011 Genome Res. 21:915-24; 
Machado et al 2014 Mol Microbiol. 2014 92:756-76). As such we cannot make the 
null mutant parasite lines suggested by reviewer 2.
2. Reviewer 2 also suggested that we should take into account the work from the 
McHugh laboratory regarding their recent views of the activity of exonucleases such 
as SNM1A, in ICL repair and as such the following changes have been made to the 
manuscript.
We have altered the start of the 4th paragraph in the introduction that outlines DNA 
replication/mammalian ICL repair systems to reflect these new views and have cited 
appropriate references. This section now reads:
“In dividing mammalian cells resolution of ICLs encountered during DNA 
replication can occur by different mechanisms. In one system stalling of a 
DNA replication fork(s) promotes the RPA-mediated recruitment of 
endonucleases (e.g. XPF-ERCC1) and facilitates ‘unhooking’ of the lesion 
[33; 34]. Similar to the transcriptional ICL repair mechanism, downstream 
processing events involving exonuclease (e.g. SNM1A) and TLS activities 
then take place with repair of dsDNA breaks (DSBs) that arise during this 
mechanism occurring via homologous recombination (HR) [33]. In a second 
system, known as the Fanconi Anaemia (FA) pathway,….”
Our studies indicate that the DNA replication/ICL repair mechanism described above 
and involving the concerted SNM1A and homologous recombination activities does 
not occur in Trypanosoma brucei: Our data clearly shows that TbSNM1 (homologue 
of the human SNM1A) and MRE11 (homologous recombination) activities are non-
epistatic. We have modified an existing sentence in the discussion to emphasis this 
difference. This now reads:
“The unhooked sequence may undergo nucleolytic processing prior to the 
2nd incision event in an SNM1-independent mechanism, distinct from the 
situation observed in mammalian cells [33], possibly involving TbEXO1.”.
Additionally, we have altered the Figure 6 legend to read:
“In an SNM1-independent mechanism, and distinct from the situation 
observed in mammalian cells [33], the unhooked ICL may undergo 
nucleolytic processing (TbEXO1)”.
We believe these changes take into account the views proposed by the McHugh 
laboratory on mammalian ICL repair systems that operate during DNA replication 
and further emphasise that the mechanisms which function in higher eukaryote, model 
organisms do not necessarily relate to the situation that takes place in early branching 
eukaryotes such as Trypanosomes
I would like to thank the reviewers for their constructive comments that I feel have 
helped us improve the manuscript.
I look forward to hearing from you in the near future.
Yours faithfully
Dr Shane Wilkinson
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Abstract 
Interstrand crosslinks (ICLs) represent a highly toxic form of DNA damage that can block 
essential biological processes including DNA replication and transcription. To combat their 
deleterious effects all eukaryotes have developed cell cycle-dependent repair strategies that co-
opt various factors from ‘classical’ DNA repair pathways to resolve such lesions. Here, we 
report the first systematic dissection of how ICL repair might operate in the Trypanosoma 
brucei, the causative agent of African trypanosomiasis, and demonstrated that this diverged 
eukaryote expresses systems that show some intriguing differences to those mechanisms 
present in other organisms. Following the identification of trypanosomal homologues encoding 
for CSB, EXO1, SNM1, MRE11, RAD51 and BRCA2, gene deletion coupled with phenotypic 
studies demonstrated that all the above factors contribute to this pathogen’s ICL REPAIRtoire 
with their activities split across two epistatic groups. We postulate that one network, which 
encompasses TbCSB, TbEXO1 and TbSNM1, may operate throughout the cell cycle to repair 
ICLs encountered by transcriptional detection mechanisms while the other relies on 
homologous recombination enzymes (MRE11, RAD51 and BRCA2) that together help resolve 
lesions responsible for the stalling of DNA replication forks. This study not only sheds light 
on the conservation and divergence of ICL repair in one of only a handful of protists that can 
be studied genetically, but offers the promise of developing or exploiting ICL-causing agents 
as new anti-parasite therapies. 
21. Introduction
Spread by the hematophagous feeding behaviour of tsetse flies, protozoan parasites belonging 
to the Trypanosoma brucei species complex are responsible for a group of human and animal 
infections collectively known as African trypanosomiasis [1]. In terms of their medical 
importance, these pathogens have caused several major epidemics across sub-Saharan Africa 
with the last ending at the turn of the millennium [2]. Based on concerted efforts by the World 
Health Organisation (WHO), national control programmes and non-governmental 
organisations, improved screening and new treatment approaches have been implemented 
resulting in a drastic reduction in the estimated number of cases of human African 
trypanosomiasis (HAT) from around 300,000 in 1998 to below 20,000 in 2015 [1]. Based on 
the sustained success of such schemes WHO aims to eliminate the human form of the disease 
as a public health problem by 2020, a goal that is now tantalisingly close [3, 4].
Despite significant progress being made to eradicate HAT, a potential drawback surrounds the 
therapies being used as each have their own problems; some have limited efficacy, others elicit 
unwanted side effects, most require prolonged periods of hospitalisation while many are 
expensive to synthesize, transport and/or store [5, 6]. Additionally, parasite strains refractory 
to treatment have been generated in the laboratory with some of the resistance mutations noted 
in these lines also observed in the field [7-12]. Together these issues could potentially derail 
WHOs ambition for HAT elimination. One approach that may help overcome such problems 
involves determining the mechanism of action for these existing therapies to exploit any 
findings in the development of new trypanocides. Applying this strategy to nifurtimox, one of 
the components in the clinically used nifurtimox eflornithine combination therapy, revealed 
that a mitochondrial NADH dependent type I nitroreductase, an enzyme commonly found in 
bacteria and some lower eukaryotes but absent from higher eukaryotes, plays a key role in 
catalysing the conversion of the 5-nitrofuran prodrug to its cytotoxic products [13]. Screening 
programmes utilizing this activity has identified a range of anti-T. brucei compounds. This 
revealed that chemicals containing functional groups that can promote DNA damage via 
formation of cross-linkages display significant potency against the bloodstream form of this 
parasite while exhibiting low toxicity to mammalian cells [14-17].
Generated by endogenous metabolic processes and exogenous mutagens, interstrand crosslinks 
(ICLs) represent a particularly dangerous type of DNA damage. Formed when the 
complementary strands within the DNA double helix become covalently linked, they block 
essential cellular processes that require strand separation such as DNA replication and 
transcription. If left unchecked, they can go on to promote chromosomal fragmentation, 
rearrangements, or cell death [18-21]. To conserve genome integrity, all cells exploit various 
combinations of enzymes from “classical” DNA repair pathways to help resolve ICL damage 
with these constituting an organism's so-called ICL REPAIRtoire. The precise mechanism that 
repair ICLs are unclear as different systems predominate at different stages in the cell cycle 
while evolutionarily diverse organisms employ distinct mechanisms to accomplish this task 
[22-24]. In transcriptionally active mammalian cells, the ICL-mediated stalling of an RNA 
polymerase complex results in recruitment of factors such as CSB to the lesion site with these 
subsequently interacting with other DNA repair enzymes including SNM1A, XPG and XPF-
ERCC1 [25, 26]. In a process known as ‘unhooking’, the XPF-ERCC1 and XPG endonucleases 
cleave either side of the crosslinked sugar-phosphate backbone in one of the DNA strands with 
nucleases, including SNM1A, subsequently degrading the released sequence up to and beyond 
the ICL [27-29] . The resultant gap is then filled using damage tolerant translesion synthesis 
(TLS) DNA polymerases such as Pol ζ, Pol η, Pol ι, Pol Θ or Pol κ with DNA ligase restoring 
the double strand DNA (dsDNA) structure [30-32]. Once the above has taken place, a second 
3round of nucleotide excision repair (NER), TLS DNA polymerase and DNA ligase activities 
completely removes the unhooked ICL from the second DNA strand.
In dividing mammalian cells resolution of ICLs encountered during DNA replication can occur 
by different mechanisms. In one system stalling of a DNA replication fork(s) promotes the 
RPA-mediated recruitment of endonucleases (e.g. XPF-ERCC1) and facilitates ‘unhooking’ of 
the lesion  [33, 34]. Similar to the transcriptional ICL repair mechanism, downstream 
processing events involving exonuclease (e.g. SNM1A) and TLS activities then take place with 
repair of dsDNA breaks (DSBs) that arise during this mechanism occurring via homologous 
recombination (HR) [33]. In a second system, known as the Fanconi Anaemia (FA) pathway, 
ICL-mediated stalling of a single or converging DNA replication fork(s) are recognised by the 
FANCM helicase. This promotes reversal of the replication fork(s), possibly involving 
polyubiquitination of PCNA by RAD5-like (e.g. HLTF) activities [35, 36], and recruits a large 
multi-subunit ubiquitin ligase, termed the FA core complex (FANCA, -B, -C, -E, -F, -G, -L 
and –T plus the ancillary factors FAAP20, -24 and -100), to the site of the DNA lesion [37-
40]. Once formed, this complex monoubiquitinates FANCD2/FANCI with the activated 
heterodimer drafting a series of nucleases (e.g. FANCQ (XPF)-ERCC1, MUS81-EME1, FAN1 
and FANCP (SLX4)) to the site of DNA damage [39, 41]. These cleave the DNA backbone at 
sequences 5’ and 3’ to the lesion resulting in the unhooking of the ICL from one of the DNA 
strands, formation of a single stranded gap and generation of DSBs. The single stranded gap is 
filled and integrity of the sugar-phosphate backbone is restored by TLS DNA polymerase(s) 
and DNA ligases activities. This links the parental ICL-containing DNA molecule to one of 
the newly synthesised DNA strands. The ICL is then completely removed by the concerted 
action of NER, TLS DNA polymerase and DNA ligase activities. The DSB is recognised by 
the MRN complex (MRE11/RAD50/NBS1) that guide components of the HR pathway (e.g. 
FANCD1 (BRCA2), FANCR (RAD51), FANCO (RAD51C)) to mediate recombination 
between the broken dsDNA molecule and the newly repaired DNA structure generated from 
the second round of NER/TLS DNA polymerase/DNA ligase activities. This results in 
reformation of the Y-shaped forked structure that can serve as a template for recommencement 
of DNA replication [42]. Due to the bidirectional nature of DNA replication, ICLs can cause 
the stalling of two converging DNA replication forks [43, 44]. Such X-shaped structures can 
be resolved using the mechanism outlined above although in this case two of the other newly 
synthesised DNA strands both form DSBs. In this situation, the above HR mediated repair 
systems are activated with the newly repaired DNA strand serving as template. The outcome 
of this event is formation of two dsDNA molecules and the disassociation of the replication 
machinery.
Little is known about the ICL repair mechanisms expressed by trypanosomes despite these 
parasites being highly susceptible to ICL-inducing compounds. Some components of the global 
genome NER (GG-NER) pathway (e.g. TbXPC and TbDDB) may potentially be involved in 
this process [45] while T. brucei cells null for TbSNM1, a member of the SNM1/PSO2 family 
of nucleases, display sensitivity only to ICL-inducing compounds [46]. Here, using a classical 
genetics-based approach, we analyse whether other DNA repair enzymes from the parasite’s 
transcription-coupled NER (TC-NER) (TbCSB), HR (TbMRE11, TbRAD51, TbBRCA2 and 
TbEXO1), mismatch repair (MMR; TbEXO1) and DNA damage tolerance (TbREV3 and 
TbRAD5) pathways contribute to the trypanosomal ICL repair network then assess their 
interplay with TbSNM1 and with each other.
2. Material and methods 
42.1 Parasite culture. Bloodstream form Trypanosoma brucei brucei MITat 427 (clone 221a) 
(designated as wild type) was grown in HMI-9 (Invitrogen) medium supplemented with 3 g l-1 
sodium bicarbonate, 0.014 % (v/v) β-mercaptoethanol and 10 % (v/v) foetal bovine serum 
(FBS) at 37 °C under a 5 % (v/v) CO2 atmosphere [47]. Derivatives of the ‘221’ line null for 
DNA repair enzymes (Table S1), including cells lacking Tbsnm1, Tbrad51 and Tbbrca2 [46, 
48, 49], were maintained in the above growth medium containing 2.5 μg ml−1 hygromycin, 10 
μg ml−1 blasticidin, 2 μg ml−1 puromycin and/or 2 μg ml−1 G418.
2.2. Chemicals & treatments. Agents that promote DNA damage were obtained from Sigma-
Aldrich (methyl methanesulfonate, hydroxyurea, phleomycin) or Cambridge Biosciences 
(mechlorethamine) while UV irradiation was performed with a Stratalinker UV crosslinker 
(Stratagene). The trypanocidal selective compounds blasticidin, puromycin, G418 and 
hygromycin were sourced from Melford Laboratories Ltd with difluoromethylornithine 
supplied by Prof. Mike Barrett (University of Glasgow).
2.3. Nucleic acids. The Tbcsb (Tb927.7.4080), Tbmre11 (Tb927.2.4390), Tbexo1 
(Tb927.8.3220), Tbrad5 (Tb927.7.1090) and Tbrev3 (Tb927.8.3290) open reading frames and 
flanking regions were identified following reciprocal BLAST searches of TriTrypDB 
(http://tritrypdb.org/tritrypdb/) and NCBI database (https://www.ncbi.nlm.nih.gov/) using the 
human and/or yeast orthologue as bait, and analysis of trypanosomal sequence information in 
the published literature [45, 50-52]. Deduced protein sequences were aligned to the 
counterparts expressed by other organisms using CLUSTALΩ 
(http://www.ebi.ac.uk/Tools/msa/clustalo/), domain structures evaluated using HMMR 
(http://www.ebi.ac.uk/Tools/hmmer/) and regions of homology highlighted using BoxShade 
(https://embnet.vital-it.ch/software/BOX_form.html).
2.4. Construction of null mutant lines. The vectors used to delete or interrupt a target gene 
in the T. brucei genome were generated as follows. For Tbcsb, sequences corresponding to 5′ 
and 3’ flanking regions were amplified from T. brucei genomic DNA and sequentially cloned 
either side of a resistance cassette that includes the gene encoding for hygromycin B 
phosphotransferase or neomycin phosphotransferase. The vectors designed to disrupt Tbexo1, 
Tbmre11, Tbrad5 or Tbrev3 were made in a similar way except that the amplified fragments 
were derived from the 5′ and 3’ ends of the coding sequence and these were cloned either side 
of a resistance cassette that included the gene encoding for hyg, neo, bla or pac: The primers 
and primer combinations used to generate the 5’ and 3’ sequences and the sizes of the amplified 
fragments are shown in Tables S2 and S3, and Fig. S1A. Constructs were linearized (SacI/KpnI 
for the hyg, neo and pac constructs and SacII/ KpnI for the bla vector) then transformed into 
bloodstream form T. brucei using the Human T-cell nucleofection® kit and an Amaxa® 
Nucleofector™ (Lonza AG) set to program X-001. As the T. brucei genes targeted here are 
single copy in a diploid genome, two rounds of nucleofection were needed to firstly create 
heterozygous and then null mutant lines. Integration of the Tbcsb-based DNA constructs into 
the T. brucei genome resulted in deletion of the entire open reading frame. In contrast, 
integration of the Tbexo1-, Tbmre11-, Tbrad5- or Tbrev3-based gene disruption constructs into 
the T. brucei genome resulted in deletion of 50, 37, 67 or 80 % of the corresponding open 
reading frame, respectively. The regions removed from the genome sequences are postulated 
to be needed for DNA binding (TbEXO1, TbMRE11, TbRAD5), nuclease (TbEXO1, 
TbMRE11, TbREV3), ubiquitin ligase (TbRAD5) or DNA polymerase (TbREV3) activities. 
2.5. Validation of recombinant parasites. To demonstrate that integration of a gene 
interruption cassette had occurred at the correct genetic loci and confirm that the T. brucei null 
5mutant line was no longer expressing the targeted gene(s), DNA amplification reactions were 
performed on parasite genomic DNA or cDNA templates. For gene interruption constructs, the 
primer combinations used generated amplicons specific for the intact targeted gene or the hyg-, 
neo-, pac- and/or bla-disrupted allele. For all DNA’s analysed, additional reactions aimed at 
detecting Tbtert were performed on cDNA to check the integrity of these templates and as 
loading control. The primer sequences and combinations used in cell line validation are listed 
in Tables S2 and S3.
2.6. Growth curves. Bloodstream form T. brucei in the logarithmic phase of growth were 
seeded at 1 × 104 parasites ml-1 in parasite growth medium and incubated at 37 °C under a 5 % 
(v/v) CO2 atmosphere. Each day, the cell density of each culture was measured using a 
Neubauer haemocytometer. When the number of parasites reached approximately 1 x 106 ml-
1, a new culture seeded at 1 × 104 parasites ml-1 was set up. This analysis was carried out over 
an 8 to 14 day period. Growth curves were generated using GraphPad Prism (GraphPad 
Software Inc.). All growth assays were performed in triplicate and each count at each time 
point expressed as a mean ± standard deviation. Mean generation times were calculated using 
http://www.doubling-time.com/compute.php.
2.7. Microscopy and protein analysis. Bloodstream form T. brucei were fixed in growth 
medium with an equal volume of 2 % (w/v) paraformaldehyde/PBS, washed once in phosphate 
buffered saline (PBS) and aliquots containing approximately 105 cells air dried onto a 
microscope slide. For cell cycle arrest assays, the genomes of paraformaldehyde-fixed 
trypanosomes were stained with 4′,6-diamidino-2-phenylindole (DAPI) and trypanosomes 
visualized using a Leica DMRA2 epifluorescent microscope in conjunction with a C4742-95 
digital camera (Hamamatsu Photonics). For immunofluorescence studies, paraformaldehyde-
fixed trypanosomes were permeabilized for 15 minutes in 0.5 % (v/v) Triton-X (Sigma-
Aldrich) in PBS, blocked with 50 % (v/v) FBS in PBS then labelled with rabbit anti-γH2A (Dr 
Richard McCulloch, University of Glasgow) antisera diluted 1:250 in 3 % (v/v) FBS in PBS. 
After 45 minutes, the slides were washed extensively in PBS then incubated for 45 minutes 
with Alexa-Fluor 488 goat anti-mouse (Molecular Probes) diluted 1:1000 in 3 % (v/v) FBS in 
PBS. Following further PBS washes, the parasite DNA was stained using Vectashield 
Mounting Medium containing DAPI (Vectorshield Laboratories). Images were captured using 
a Leica SP5 confocal microscope (Leica Microsystems (UK) Ltd). All images were processed 
and corrected fluorescence intensities determined using ImageJ.
For western blot analysis, protein extracts from approximately 2 x 106 trypanosomes were 
probed with rabbit anti-γH2A and rabbit anti-enolase (Prof Paul Michels, University of 
Edinburgh) antisera used at 1:1000 or 1:150,000 dilution, respectively, followed by goat anti-
rabbit IRDye™ 800CW antibody (LI-COR) diluted at 1:5,000. Detection of the near infrared 
signal was monitored using an Odyssey® CLx infrared imaging system (LI-COR). Band signal 
intensity measurements were carried out using the Analysis Tool in Image Studio™ Lite (Li-
COR Biosciences).
2.8. Susceptibility screens. All growth inhibition assays were carried out in a 96-well plate 
format (ThermoFisher Scientific). Bloodstream form T. brucei in the logarithmic phase of 
growth were seeded at 1 x 104 ml-1 (1 x 105 ml-1 for Tbrad51Δ and Tbbrca2Δ) in 200 µl growth 
medium containing different concentrations of the compound under study: For UV irradiation, 
parasites received doses up to 9000 J m−2 using a Stratalinker® UV crosslinker (Stratagene). 
After incubation at 37 °C under a 5 % CO2 atmosphere for 3 days, resazurin (Sigma Aldrich) 
was added to each well at a final concentration of 12.5 µg ml-1 (or 2.5 µg per well). The plates 
6were further incubated at 37 °C under a 5 % CO2 for 6 to 8 hours before measuring the 
fluorescence of each culture using a Gemini Fluorescent Plate reader (Molecular Devices) set 
at λEX = 530 nm and λEM = 585 nm with a filter cut off at 550 nm. The change in fluorescence 
resulting from the reduction of resazurin is proportional to the number of live cells. A 
drug/treatment concentration that inhibits cell growth by 50% (EC50) was established using the 
non-linear regression tool on GraphPad Prism (GraphPad Software Inc.).
3. Results
3.1 Identifying putative trypanosomal ICL repair enzymes
Previous studies have shown that MRE11, CSB, EXO1, RAD5 and REV3 all contribute to the 
yeast and/or mammalian ICL repair systems [25, 26, 53-55]. Using reciprocal BLAST the T. 
brucei genes encoding for homologues of these enzymes plus their flanking regions were 
identified from the TriTrypDB (http://tritrypdb.org/tritrypdb/) and NCBI 
(https://www.ncbi.nlm.nih.gov/) databases. For TbMRE11 and TbCSB, the sequences arising 
from these searches corresponded to those previously reported [45, 50, 51]. In contrast, the 
genes described here as encoding EXO1, RAD5 and REV3 orthologues have not been 
characterised. The 2394 bp hypothetical gene (Gene ID: Tb927.4.1480) assigned here as 
Tbexo1 has potential to encode for a 86.7 kDa enzyme (TbEXO1) that shares approximately 
24 % sequence identity with EXO1/HEX1 exonucleases. The T. brucei homologue contains 
within its amino terminal the XPG_N (PF00752) and XPG_I (PF00867) domains, that at this 
position in the protein sequence is a characteristic of this family of enzyme (Fig. 1A). A 4839 
bp hypothetical open reading frame (Gene ID: Tb927.7.1090), designated here as Tbrad5, was 
identified as having potential to encode for a homologue of human helicase-like transcription 
factor (HLTF) and Saccharomyces cerevisiae RAD5. The estimated 179 kDa trypanosomal 
enzyme (TbRAD5) has approximately 24 % sequence identity to this family of DNA 
helicase/ubiquitin ligases. Homology is centred on domains responsible for helicase (SNF2_N 
(PF00176); Helicase_C (PF00271)) and ubiquitin ligase (zf-RING_2 (PF13639)) activities, 
and DNA binding (HIRAN (PF08797)) (Fig. 1B) with the order in which these regions are 
arranged in the protein backbone being conserved between the parasite, yeast and fungal 
homologues. A 6181 bp hypothetical gene (Gene ID: Tb927.8.3290; designated as Tbrev3) was 
postulated to encode for a 217 kDa protein (TbREV3) that has approximately 25 % identity to 
the error-prone DNA polymerase ζ catalytic subunit expressed in S. cerevisiae and human cells. 
The parasite enzyme has a domain structure typical of REV3 subunits containing a DNA 
polymerase family B, exonuclease domain (PF03104) towards its amino terminal and a DNA 
polymerase family B (PF00136) followed by C4-type zinc finger (PF14260) towards its 
carboxyl terminal (Fig. 1C).
In humans, the FA pathway plays a major role in resolving ICLs encountered during DNA 
replication. It is now recognised that other eukaryotes also express this system although the 
activities involved vary between species [56, 57]. To determine the extent of this system in T. 
brucei, FA proteins (complete or specific domains) from humans, Danio rerio, Drosophila 
melanogaster, Arabidopsis thaliana and S. cerevisiae were used to search for trypanosomal 
homologues held on the TriTryp and NCBI databases. Out of the 26 sequences examined, T. 
brucei possessed discernible homologues for 7 including BRCA2 (FANCD1), RAD51 
(FANCR), RAD51C (FANCO) and XPF (FANCQ), enzymes that play a role in this parasite’s 
HR and NER pathways (Fig. 1D) [45, 48, 49, 58]. All of the sequences identified were so-
called FA effector proteins with none corresponding to components of the FA core complex 
(FANCA, -B, -C, -E, -F, -G, -L, -M and –T), recruitment factors (FANCD2A and -I) or FA 
associate protein (FAAP10, -16, -20, -24 and -100).
73.2 Construction and validation of T. brucei single null mutant lines
To evaluate whether the identified sequences were involved in the parasite’s ICL repair 
network, cells null for each gene were generated. To achieve this, DNA fragments containing 
the 5’ or 3’ flanking or coding sequences from the gene of interest were amplified from wild 
type T. brucei genomic DNA, digested with restriction enzymes (5’ sequences were processed 
with SacI and XbaI while 3’ sequences were treated with ApaI and KpnI) then cloned either 
side of a drug resistance cassette that contains the gene encoding for the hygromycin B 
phosphotransferase (hyg) or neomycin phosphotransferase (neo) (Fig. S1A). The gene 
deletion/disruption constructs were linearized with SacI/KpnI and the fragments transformed 
into bloodstream form T. brucei. To remove both allelic copies of the target gene (all sequences 
tested were single copy genes) two rounds of nucleofection were performed to firstly create 
heterozygous and then null mutant lines, with clonal populations of the latter tentatively 
designated as T. brucei TbcsbΔ, Tbmre11Δ, Tbexo1Δ, Tbrad5Δ and Tbrev3Δ. The predicted 
effect of each gene disruption event with each integration fragment is depicted (Figs. S1B-G). 
To confirm that integration of the introduced DNA fragments had occurred into the correct 
genetic loci, DNA amplification reactions using gDNA as template were performed. Such 
PCRs used primer combinations that generated fragments specific for the intact targeted gene 
or each disrupted allele (Fig. 2; Figs. S1B-G). For example, when using a primer combination 
designed to detect intact Tbcsb (Tbcsb-KO1/Tbcsb-q2) DNA amplification generated a band 
of the expected size (approximately 1.4 kb) from gDNA extracted from wild type parasites 
with no band(s) observed in DNA isolated from T. brucei TbcsbΔ cells (Fig. 2A upper panel; 
Fig. S1B). In contrast, primer combinations that detect the hyg- (Tbcsb-KO1/hyg) or neo- 
(Tbcsb-KO1/neo) interrupted alleles generated amplicons of the predicted size (approximately 
1.7 and 1.5 kb, respectively) but only from the gDNA purified from T. brucei TbcsbΔ null 
mutant line: No band(s) was observed when using T. brucei wild type gDNA as template. 
To show that each T. brucei null mutant line was not expressing the targeted gene, DNA 
amplification reactions were performed on cDNA templates using primer combinations that 
generated fragments specific for the intact, targeted gene (Fig. 2). For example, when using a 
primer combination designed to generate a Tbcsb specific amplicon (Tbcsb-q1/Tbcsb-q2), a 
single band of the expected size (approximately 140 bp) was observed in cDNA synthesised 
from total RNA extracted from wild type parasites with no band(s) detected in material derived 
from T. brucei TbcsbΔ (Fig. 2A lower panel). To confirm that RNA had been extracted from 
both cell lines and that cDNA had indeed been made, control reactions amplifying Tbtert were 
conducted in parallel. For all tested samples a band of the expected size (approximately 100 
bp) was observed.
The above PCR-based strategies were extended to validate T. brucei lines null for Tbmre11, 
Tbexo1, Tbrad5 or Tbrev3 (Figs. 2B-E). In each case, this confirmed that integration of the 
input DNA fragments had successfully occurred into the parasite genome and established that 
the deleted transcript was not being expressed in the appropriate null mutant line.
3.3 Characterisation of T. brucei single null mutant lines
To assess whether lack of a given DNA repair activity affected parasite growth, the cumulative 
growth properties of null mutants was determined (Fig. S2A). In most cases (Tbexo1Δ, TbcsbΔ, 
Tbrad5Δ and Tbrev3Δ), the lines grew at the same rate as wild type with the cultures having a 
doubling time of around 370 minutes. In contrast, cells lacking TbMRE11 exhibited a slight 
growth defect, having a mean generation time of 450 minutes, in keeping with previous 
observations [50, 51]. To examine these growth characteristics further, the cell cycle 
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lines (Fig. S2B). Asynchronous cultures of bloodstream form parasites in the exponential phase 
of growth were fixed and the ratio of nuclear (N) and mitochondrial (known as the kinetoplast 
(K)) genomes within each trypanosome determined with this providing a reliable marker for 
where that cell is within the cell cycle [59-61]. T. brucei in the G1/S phase of the cell cycle 
have a 1K1N arrangement, those that possess a 2K1N ratio are said to be in the G2/M phase 
while trypanosomes displaying a 2K2N profile are in the post M phase. For wild type T. brucei, 
Tbsnm1Δ and TbcsbΔ, most cells (approximately 75%) in the asynchronous population were 
in G1/S phase, with about 20% in the G2/M phase and around 5% in the post M phase of the 
cell cycle. In contrast, fewer Tbmre11Δ cells (approximately 55%) were in the G1/S phase, 
with a concomitant increase (approximately 40%) of cells in the G2/M phase of the cell cycle 
(Fig. S2B). Therefore, the increased mean generation time exhibited by TbMRE11-deficient 
parasites is mostly due to a delay at the G2/M phase of the cell cycle. In other organisms, 
MRE11 as part of the MRN complex, functions to recognise DSBs generated during DNA 
replication then aids in recruitment of ATM to the site of DNA damage. Perturbation of this 
sensor mechanism effects downstream ATM-dependent processes such as progression through 
the G2/M checkpoint [62].
To evaluate whether deletion of Tbcsb, Tbmre11, Tbexo1, Tbrad5 or Tbrev3 from the T. brucei 
genome altered the parasites sensitivity to DNA damage, the null mutants were grown in the 
presence of hydroxyurea, phleomycin or methyl methanesulfonate, or cultured following 
exposure to a single dose of UV, and the EC50 values towards each treatment determined (Table 
1; Fig. S2C & D). Cells lacking TbCSB were 5-fold more susceptible to UV than wild type, in 
keeping with previous observations [45], while parasites lacking TbEXO1 displayed an 
increased sensitivity (2-fold) towards phleomycin. In keeping with the published literature, 
TbMRE11 deficient parasites were more susceptible to phleomycin (12-fold) and methyl 
methanesulfonate (2.5-fold), agents that promote DSBs (Table 1: Figs. S2C & D) [50, 51]. 
Intriguingly, these mutants were also shown to be 4.9-fold more sensitive to UV, a trait not 
previously reported, with this phenotype potentially stemming from DSB formation caused by 
the arrest of replication forks at UV-induced damaged sites [63]. Cells lacking TbRAD5 and 
TbREV3 were as sensitive to all the DNA damaging treatments tested as wild type indicating 
that these do not play a front line role in resolving the lesions generated by the tested treatments. 
3.4 Susceptibility of T. brucei single null mutants towards mechlorethamine
The above growth inhibition assays were extended to investigate the phenotype displayed by 
T. brucei null mutants towards mechlorethamine, an archetypal ICL inducing agent. The 
resultant data was plotted as dose response curves from which EC50 values were extrapolated 
(Fig. 3).  Previous work has shown that TbSNM1 plays an important role in resolving the 
damage caused by mechlorethamine with our data confirming this earlier finding [46]: Cells 
lacking TbSNM1 are >8-fold more susceptible to this compound as compared to controls. A 
similar alteration in sensitivity was also observed in cells deficient in TbMRE11, TbCSB or 
TbEXO1 although the difference in EC50 values displayed by these 3 mutants relative to wild 
type was not as great as that noted for Tbsnm1Δ cells; Tbmre11Δ, TbcsbΔ and Tbexo1Δ cells 
were 3-, 4- and 2-fold more susceptible to mechlorethamine than wild type, respectively (Figs. 
3A-C) This could suggest the relative importance of each enzyme in T. brucei's so-called ICL 
REPAIRtoire. In contrast, cells lacking TbRAD5 or TbREV3 displayed wild type sensitivities 
towards the ICL inducing agent indicating they play no significant role in resolving this type 
of damage (Figs. 3D-E). To confirm that the above phenotyping was due to the engineered 
gene deletion/disruption events and not due to off target effects, the susceptibility of all mutants 
towards the non-DNA damaging trypanocidal agent difluoromethylornithine was analysed 
9(Fig. S3). In all cases the null lines were as equally sensitive to this compound as each other 
and the wild type, providing evidence that the above susceptibility profiles are specific for each 
DNA damaging treatment.
As TbMRE11 functions in T. brucei’s HR pathway, the above studies were extended to 
evaluate whether parasites deficient in other components of this repair system (TbBRCA2 or 
TbRAD51) exhibited altered susceptibilities towards mechlorethamine: TbBRCA2 and 
TbRAD51 correspond to two known FA proteins, FANCD1 and FANCR, respectively (Fig. 
1D). From the resultant dose response curves and EC50 values (Fig. S4), parasites lacking 
TbRAD51 or TbBRCA2 were shown to be 6- or 3-fold more sensitive to the ICL inducing 
agent than controls, respectively, thus implicating these activities in the trypanosomal ICL 
repair network. The above data implicates TbSNM1, TbCSB, TbEXO1, TbMRE11, TbRAD51 
and TbBRCA2 in the bloodstream form T. brucei ICL repair system and thus constitute a part 
of this parasite's ICL REPAIRtoire.
3.5 Mechlorethamine-induced γH2A formation in T. brucei single null mutants 
Nuclear genome damage in many eukaryotes including T. brucei often leads to phosphorylation 
of H2A to form γH2A an alteration frequently used to monitor for DNA damage including 
DSB formation [61, 64, 65]. To determine if mechlorethamine can promote this post-
translational modification in T. brucei, protein extracts generated from wild type parasites 
continuously grown in the presence of mechlorethamine (30, 10 and 3 µM) were probed for 
γH2A formation using an antiserum against this modified histone (Fig. 4A), with the band 
intensities normalised against untreated controls (Fig. 4B): A similar analysis was performed 
on the same extracts using enolase as loading & normalisation control. In wild type cells and 
at all mechlorethamine concentrations tested, an increase in the γH2A signal was observed over 
the first 4 hours of treatment with the marker intensity then declining over the next 4 hours 
indicating resolution of the DNA damage. When these studies were extended to the null lines, 
various outcomes were observed. TbSNM1- and TbEXO1-deficient cells behaved similarly to 
wild type cells. In TbcsbΔ cells, the formation of γH2A was delayed, and continued to increase 
throughout the experiment suggesting that these parasites may be unable to effectively 
recognise and resolve any ICL-induced DSBs. Intriguingly, when following γH2A formation 
in cells lacking TbMRE11, no alteration in signal intensity was noted at any time point across 
any of the mechlorethamine concentrations used indicating that this enzyme plays an important 
role in phosphorylation of histone H2A in response to DNA damage [66-68].
To further evaluate mechlorethamine and DNA damage in mutant lines, cells treated for 4 hours 
in the presence of the ICL-inducing agent (30 µM) were analysed using immunofluorescence 
microscopy to detect γH2A (Fig. 4C). For wild type, Tbsnm1Δ, TbcsbΔ and Tbexo1Δ, a 
discrete signal was observed within the nucleus showing that DNA damage was taking place. 
This pattern also was detected in wild type, Tbsnm1Δ and Tbexo1Δ cells that had been treated 
with mechlorethamine for 2 hours but not in TbcsbΔ parasites. In contrast, and confirming the 
western blot data, no signal was observed in mechlorethamine treated TbMRE11 null parasites.
3.6 Assessing the interplay between trypanosomal ICL repair enzymes
To evaluate the functional relationship between components of the trypanosomal ICL repair 
system, the genes encoding for TbEXO1, TbMRE11 or TbCSB were disrupted in a Tbsnm1-
deficient T. brucei line to create a series of double null mutant lines. Additionally, TbRAD5 
and TbREV3 although not primarily involved in resolving ICLs, were also taken forward to 
determine whether their activities in this repair network becomes apparent in the absence of 
TbSNM1: The role of some yeast factors in ICL repair are only apparent when the activity of 
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another DNA repair protein is missing [69]. To generate the double null mutant lines, the hyg- 
and neo-based integration vectors for each targeted gene were linearised and sequentially 
transformed into T. brucei Tbsnm1Δ cells (in this mutant line, Tbsnm1 has been disrupted using 
vectors based around resistance cassettes that includes the gene encoding for blasticidin-S-
deaminase (bla) or puromycin N-acetyltransferase (pac) [46]). Following selection, all putative 
double null clones were validated using the PCR-based strategies outlined previously with this 
confirming that the introduced DNA fragments had integrated into the T. brucei genome and 
that the recombinant parasites were no longer expressing both disrupted genes (Fig. 2).
Analysis of the double null mutants revealed that parasites lacking TbSNM1 and TbCSB, 
TbEXO1, TbRAD5 or TbREV3 grew roughly at the same rate as wild type while cells deficient 
in TbSNM1 and TbMRE11 exhibited a slightly longer mean generation time comparable to 
that noted for the T. brucei Tbmre11Δ line. Additionally, phenotypic screening with DNA 
damaging treatments demonstrated that the susceptibility displayed by the double null mutant 
lines were generally equivalent to the more sensitive phenotype shown by the single null for 
each gene pairing (Table 1). For example, all Tbcsb-deficient cell types were approximately 5-
fold more susceptible to UV than wild type or Tbsnm1Δ such that the Tbsnm1ΔTbcsbΔ line 
exhibited an EC50 similar to TbcsbΔ parasites. As such, lack of TbSNM1 and TbCSB activities 
in the same cell does not lead to an increase in susceptibility to UV. The only situation where 
a combinatorial effect on susceptibility was noted related to cells lacking TbSNM1 and 
TbMRE11. Intriguingly, such double null mutant parasites were more than 20-fold more 
sensitive to UV-induced lesions relative to T. brucei wild type and Tbsnm1Δ, and 4-fold more 
sensitive relative to Tbmre11Δ (Table 1). This difference could reflect that TbSNM1 does play 
a secondary role in resolving UV-induced damage, a phenotype that is only apparent in cells 
compromised in the HR pathway.
The phenotypic screens were extended to investigate the susceptibility that T. brucei double 
null mutants display towards mechlorethamine with the resultant data plotted as dose response 
curves from which EC50 values were extrapolated (Fig. 3). This revealed that cells lacking 
TbSNM1 and TbMRE11 were hypersensitive towards this ICL-inducing agent relative to wild 
type and the Tbsnm1Δ or Tbmre11Δ lines showing that these two nucleases function in a non-
epistatic fashion and do not operate in the same ICL repair system (Fig. 3C). In contrast, 
parasites deficient in TbSNM1 and TbCSB or in TbSNM1 and TbEXO1 exhibit dose response 
sensitivities to mechlorethamine similar to Tbsnm1Δ parasites, with the double null lines being 
more susceptible to this compound than wild type and TbcsbΔ or Tbexo1Δ cells (Figs. 3A & 
B). The type of patterns observed indicate that TbSNM1 functions epistatically with TbCSB 
and TbEXO1. When the susceptibility phenotype of trypanosomes lacking TbSNM1 and 
TbRAD5 or TbREV3 towards mechlorethamine was assessed, dose response curves similar to 
that obtained using control lines were observed (Figs. 3D & E). This suggests that TbRAD5 
and TbREV3 do not play a role in the T. brucei ICL repair networks. 
To further investigate any epistatic/non-epistatic relationships, double null lines lacking 
TbCSB and TbMRE11, TbEXO1 and TbMRE11 or TbCSB and TbEXO1 activities were made 
and the resultant lines validated (Figs. 5A-C). Evaluation of dose response curves of parasites 
lacking TbCSB and TbEXO1 towards mechlorethamine revealed that these cells exhibited a 
susceptibility pattern similar to TbcsbΔ trypanosomes, with the double null lines being more 
sensitive to this treatment than wild type and Tbexo1Δ cells (Fig. 5D). This clearly 
demonstrates that these Tbcsb is epistatic with respect to Tbexo1 in the T. brucei ICL repair 
system. In contrast, TbcsbΔTbmre11Δ and Tbexo1ΔTbmre11Δ trypanosomes were 
hypersensitive to this ICL-inducing agent relative to wild type cells and the corresponding 
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single null mutant lines providing evidence that TbCSB and TbEXO1 both function in a non-
epistatic fashion with respect to TbMRE11 and as such the former two activities operate in an 
ICL repair system distinct from that the one the latter is involved in (Figs. 5E and F). 
All of the double null mutant data clearly shows that T. brucei expresses at least two distinct 
ICL repair systems with one involving the concerted action of TbSNM1, TbCSB and TbEXO1 
with the other using TbMRE11. It is tempting to speculate that given TbCSB plays a role in 
TC-NER and that the former SNM1-dependent pathway functions to resolve ICLs encountered 
during DNA transcription while the MRE11-dependent system helps remove ICLs encountered 
during DNA replication.
4. Discussion
Throughout its cell and life cycle T. brucei may be exposed to a range of endogenous 
metabolites and environmental stimuli that in other organisms result in ICL formation [70-72]. 
Despite ICLs being highly toxic, very little is known about the mechanisms T. brucei employs 
to resolve such lesions. The ICL repair networks expressed in yeast and mammalian cells can 
be distinguished by how these systems are activated and the factors involved [18, 21, 22, 24, 
73]. Throughout the cell cycle, but most prominently during the G1/G0-phases, replication-
independent systems operate with these mechanisms triggered by global genome surveillance 
processes (by GG-NER) or stalling of transcription complexes (by TC-NER) [25, 26, 74]. 
Following lesion detection, networks are invoked that involve components from the NER 
and/or MMR pathways which together unhook then resect the ICL from the genome with any 
excised genetic material replaced by TLS [27, 30]. In contrast, during the S-phase of the cell 
cycle, replication-dependent mechanism(s) function to eliminate ICLs [35, 39-41, 69, 75]. In 
such networks, recognition of an ICL stalled DNA replication fork(s) occurs through 
components of the FA or Fanconi-like systems that firstly cause reversal of the replication 
fork(s) then guide predominantly HR effector proteins to the site of damage. In conjunction 
with the endonucleases centred on XPF-ERCC1 activity, these cooperate to remove and replace 
the cross linkage from the genome using homologous sequences as a repair template. Here, 
using comparative genomics in conjunction with classical genetic approaches we have 
identified several putative trypanosomal ICL repair proteins and established whether the in 
silico assignments were of biological relevance. This revealed that enzymes from the T. brucei 
NER, HR and/or MMR pathways contribute to this organism’s ICL REPAIRtoire to resolve 
damage generated by mechlorethamine and that these activities function across two distinct 
networks. 
An informatics approach was employed to determine the extent of the T. brucei ICL 
REPAIRtoire. Using protein sequences from representative members of the yeast and/or 
mammalian ICL repair systems as bait, genome database searches were performed identifying 
trypanosomal homologues of the TC-NER helicase CSB, the MMR/HR exonuclease EXO1 
and the REV3 catalytic subunit of pol ζ involved in error-prone TLS were identified. 
Additionally¸ the ICL repair specific nuclease TbSNM1, several HR components including 
MRE11, RAD51 and BRCA2, and RAD5, a DNA helicase/ubiquitin ligase that can promote 
HR in a template switching, error-free DNA damage tolerance pathway, were found. 
Intriguingly, no discernible homologues for any component of the FA core complex (FANCA, 
-B, -C, -E, -F, -G, -L and –T plus the ancillary factors FAAP20, -24 and -100), recruitment 
factors (FANCD2A and –I) or FA-like proteins (Mph1 and Slx4) were identified suggesting 
the ICL-mediated stalling of DNA replication forks is recognised by trypanosomal mechanisms 
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distinct from those typically expressed by other eukaryotes with this potentially triggering 
unusual downstream responses. 
In many cases, the use of null mutant lines has provided the primary route for the identification 
of which DNA repair factors function in an organism’s ICL REPAIRtoire and in deciphering 
how these components interact [55, 69, 76, 77]. Transferring this approach to T. brucei, lines 
lacking a single potential ICL repair factor were made (TbCSB, TbEXO1, TbMRE11, 
TbRAD5 or TbREV3) or sourced (TbSNM1, TbRAD51 or TbBRCA2 [46, 48, 49]) with these 
subsequently phenotyped using mechlorethamine as a selective agent. For most parasite lines 
tested, an increased susceptibility to the ICL-inducing agent was observed, demonstrating that 
TbSNM1, TbCSB, TbEXO1, TbMRE11, TbRAD51 and TbBRCA2 all contribute to the 
trypanosomal ICL REPAIRtoire. Comparison of the degree of susceptibility of each mutant in 
relation to controls suggests that TbSNM1 may play a prominent role in resolving crosslinks 
while TbCSB, TbMRE11, TbRAD51 and TbBRCA2 all represent important factors in these 
repair systems: Tbsnm1Δ parasites exhibited the highest fold (around 7.5-fold) difference in 
susceptibility while TbcsbΔ, Tbmre11Δ, Tbrad51Δ and Tbbrac2Δ cells displayed moderate 
(between 3- to 5-fold) changes. In the case of TbEXO1, cells lacking this exonuclease 
displayed about a 2-fold increase in sensitivity indicting that this enzyme may play an ancillary 
role in the trypanosomal ICL repair network. When these screens were extended to TbRAD5- 
or TbREV3-deficient parasites no obvious differences in susceptibility was observed. As with 
other organisms, trypanosomes express several error-free and error-prone DNA damage 
tolerance mechanisms and it is plausible that these other systems may complement for the lack 
of TbRAD5 or TbREV3 activity in the corresponding T. brucei null line [78].
Resolution of ICLs involves the concerted action of various enzymes from different ‘classical’ 
DNA repair pathways operating across several cell cycle dependent networks and all within a 
single cell. In yeast, the interplay of ICL repair factors and their assignment to a given pathway 
frequently involves use of fungal lines lacking multiple DNA repair activities and determining 
their susceptibility towards an ICL-inducing agent [55, 69, 76, 77]. Such studies can then help 
inform the situation in other organisms. To evaluate the interactions of TbSNM1, TbCSB, 
TbEXO1 and TbMRE11, T. brucei lines lacking various combinations of two of these activities 
were generated with the parasites subsequently phenotyped against mechlorethamine. This 
revealed that TbSNM1, TbCSB and TbEXO1 function in one T. brucei ICL repair system with 
TbMRE11 operating as part of a second distinct network. This situation resembles that noted 
in other organisms although there are some key differences. In S. cerevisiae, PSO2 (the yeast 
SNM1 homologue) displays a non-epistatic interaction with EXO1 and all tested DSB repair 
protein, including MRE11 [55, 77, 79, 80]. It also associates with several NER factors such as 
RAD1 (XPF), RAD3 (XPD), RAD4 (XPC) and RAD14 (XPA) [22, 77] although whether it 
interacts with RAD26 (the yeast CSB homologue) remains unclear [22]. In humans, the role 
played by SNM1 is reportedly more complex partly because each cell can express multiple 
isoforms of this family of nuclease [81]. In the case of SNM1A, the human homologue most 
like yeast PSO2, a direct interaction with CSB has been established [26] with associations also 
noted for other NER factors such as XPC, DDB2 and XPF–ERCC1 [28, 74]. In a situation 
contrary to that observed in yeast and T. brucei, SNM1A also appears to play a role in 
replication-dependent ICL resolving mechanisms as it reportedly co-localises with the HR 
factors such as MRE11 and BRCA1 while human cells with depleted levels for this activity 
exhibit an increase in replication associated DSBs [28, 82]. Additionally, human cells also 
express a second SNM1/PSO2 isoform called SNM1B that has been shown to physically 
interact with MRE11 via an MRN binding site with this activity facilitating direct DNA repair 
at the site of stalled DNA replication forks, a HR-dependent process that occurs during S-phase 
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of the cell cycle [81, 83, 84]. Therefore, it appears that in single-celled eukaryotes members of 
the SNM1/PSO2 family function only in replication-independent ICL repair systems while in 
higher eukaryotes this class of nuclease additionally play roles in replication-dependent ICL 
repair processes.
Based on the pathways reported in other organisms coupled with observations made by 
ourselves and by Machado et al [45], we postulate that in bloodstream form T. brucei ICLs 
encountered throughout the cell cycle as a result of global genome surveillance through GG-
NER (e.g. TbXPC, TbDDB, TbRAD23) or transcription complex stalling by TC-NER (e.g. 
TbCSB) recognition mechanisms trigger TbXPF-TbERCC1 (and possibly XPG) incision of 
one DNA strand at sites flanking the ICL (Fig. 6A). The resultant unhooked sequence 
subsequently undergoes nucleolytic processing, a process carried out by TbSNM1 (and 
possibly TbEXO1), up to and beyond the crosslink, leaving a single nucleotide tethered to the 
complementary strand. RPA binds to the single stranded gap generated by the unhooking 
activity that via activated PCNA recruits TLS DNA polymerases to this site. These in 
conjunction with DNA ligases restore the integrity of the DNA strand. To completely remove 
the crosslinked nucleotide from the other DNA strand a second round of incision followed by 
TLS activity occurs to generate the undamaged dsDNA structure. In contrast and representing 
a DNA replication-dependent mechanism, two replication forks converge upon an ICL to form 
an X-shaped structure (Fig. 6B). Following recognition by an unknown mechanism that does 
not involve the FA core or FA-like proteins, incision of one DNA strand at sites flanking the 
ICL occurs possibly through the action of TbXPF-TbERCC1, TbMUS18 and/or TbFAN1. This 
results in unhooking of the ICL from one DNA strand, formation of a single stranded gap and 
generation of DSBs, with the latter detected through the TbMRE11-mediated formation of 
γH2A. The single stranded gap can be filled as described above through TLS DNA 
polymerase/DNA ligase activities with the unhooked sequence removed and replaced by a 
second round of incision and TLS: The unhooked sequence may undergo nucleolytic 
processing prior to the 2nd incision event in an SNM1-independent mechanism, distinct from 
the situation observed in mammalian cells [33], possibly involving TbEXO1. The DSBs can 
then be repaired by HR involving TbRAD51 and TbBRCA2, using the newly formed dsDNA 
as a template. The two proposed trypanosomal pathways both employ TLS activities to fill 
single strand gaps that are associated with unhooking events. However certain DNA 
polymerases such as pol ζ are error prone and as such their activity may introduce base 
mismatches in the newly ‘repaired’ sequence. To overcome such secondary lesions, MMR 
mechanisms possibly involving TbEXO1 can operate although these may create point 
mutations relative to the initial sequence.
We have now shown that T. brucei expresses several enzymes from a number of classical DNA 
repair pathways that also function to resolve ICLs. As in other organisms, these activities 
operate across multiple, distinct pathways that we postulate function to fix lesions encountered 
at different points in the cell cycle. The comparative analysis performed here on a relatively 
small number of targets has already shown that the ICL resolving mechanisms employed by T. 
brucei share similarities to those expressed by other eukaryotes but has also highlighted some 
intriguing differences. By further unravelling the ICL repair systems additional variations may 
be identified. Such disparities between the trypanosomal and mammalian networks could 
identify potential targets that may be exploitable in terms of drug development such that the 
specific inhibition of a parasite ICL repair factor(s) may render the pathogen more susceptible 
to compounds that promote ICL formation.
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Figure 1: Sequence analysis of potential trypanosomal ICL repair enzymes. (A). Sequences corresponding to the XPG N-terminal (XPG_N) 
and XPG_I protein (XPG_I) domains of TbEXO1 (accession number XP_847153) were aligned with the equivalent regions from the H. sapiens 
(HsHEX1; AAC32259) and S. cerevisiae (ScEXO1; NP_014676) orthologues. (B). Sequences corresponding to the HIRAN, SNF2 family N-
terminal (SNF2_N; blue box), RING finger (zf-RING_2; purple box) and helicase conserved C-terminal (Helicase_C; red box) domains of 
TbRAD5 (XP_845733) were aligned with the equivalent regions from the H. sapiens (HsHLTF; NP_001305864) and S. cerevisiae (ScRAD5; 
NP_013132) orthologues. (C). Sequences corresponding to the DNA polymerase family B, exonuclease (DNA_pol_B_exo1), DNA polymerase 
20
family B (DNA_pol_B) and C4-type zinc-finger of DNA polymerase delta (zf-C4pol) domains, and to the putative REV7 binding site of TbREV3 
(XP_847160) were aligned with the equivalent regions from the H. sapiens (HsREV3; NP_002903) and S. cerevisiae (ScREV3; CAA97873) 
orthologues. In the alignments, conserved residues are highlighted in black or grey. (D). Comparison of the Fanconi Anaemia (FA) pathway 
components expressed by Danio rerio (D. rerio; fish), Drosophila melanogaster (Drosophila; insect), Arabidopsis thaliana (A. thaliana; plant), 
Saccharomyces cerevisiae (S. cerevisiae; yeast) and T. brucei in relation to the system possessed by humans (H. sapiens). Trypanosomal FA 
factors were identified by reciprocal BLAST analysis using human Fanconi anemia (FA) factors as bait. An oval indicates the possibility for the 
presence of a given factor whereas no oval indicates that that component is most probably absent. In mammalian cells, the FA ICL repair pathway 
can be subdivided the FA core complex (black ovals), recruitment factors (white ovals), FA effectors (grey ovals). In addition to lacking sequences 
corresponding to the FA core (FANCA, -B, -C, -E, -F, -G, -L and –T) or recruitment (FANCD2A and –I) complexes, no discernible T. brucei 
homologues for many of the FA associated proteins (FAAP10, -10, -20, -24 and -100) were detected. Figure layout derived from Dong et al., 2015 
[57].
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Figure 2: Validation of T. brucei null mutant lines. (A-E; upper panels). Amplicons (in 
kbp) corresponding to intact Tbsnm1 (A-E), Tbcsb (A), Tbexo1 (B), Tbmre11 (C), Tbrad5 (D) 
or Tbrev3 (E) and their hyg-, neo-, pac- or bla-disrupted counterparts were generated from 
template genomic DNAs extracted from the various T. brucei lines indicated.  (A-E; lower 
panels). Amplicons (in bp) corresponding to intact Tbsnm1 (A-E), Tbcsb (A), Tbexo1 (B), 
Tbmre11 (C), Tbrad5 (D) and Tbrev3 (E) were generated from template cDNAs derived from 
total RNA extracted from the various T. brucei lines indicated. The integrity of cDNAs (and 
hence RNAs) was evaluated by amplification of a 108 bp control fragment, Tbtert. The primer 
sequences and combinations used for each amplification are listed in Tables S2 and S3, 
respectively.
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Figure 3: Susceptibility of T. brucei null mutants towards mechlorethamine. Left hand 
panels: Dose response curves and EC50 values (in µM) of T. brucei lines towards 
mechlorethamine. All data points are mean values ± standard deviations from experiments 
performed in quadruplicate. Right hand panels: The susceptibility of the T. brucei single and 
double null mutant lines against mechlorethamine, as judged by their EC50 values, were 
compared and expressed as a fold difference relative to wild type.
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Figure 4: γH2A formation in mechlorethamine treated T. brucei. (A). T. brucei wild type, 
Tbsnm1Δ, TbcsbΔ, Tbexo1Δ and Tbmre11Δ were treated with 30 µM mechlorethamine. Cell 
lysates were generated at time intervals (0, 1, 2, 4, 6, and 8 hours) and analysed by western blot 
using anti-T. brucei enolase (loading control) and anti-T. brucei γH2A antiserum. Treatment 
with other mechlorethamine concentrations (10 and 3 µM) resulted in similar γH2A responses 
(data not shown). (B). The γH2A and enolase signal intensities obtained from western blots 
containing extracts from three independent mechlorethamine treated cultures were determined 
using Image Studio™ Lite (Li-COR Biosciences) and normalised against untreated controls. 
The data is expressed as a mean ± standard deviation relative fold difference. (C). The pattern 
of DNA (blue) and γH2A (green) staining in T. brucei treated (+) for 4 hours with 
mechlorethamine (HN2) was compared with signals observed in untreated (-) cells. The cells 
were examined by florescence microscopy and the brightfield (BF) image captured. Scale bar 
= 5 µM.
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Figure 5: Evaluating the interplay between TbCSB, TbMRE11 and TbEXO1 in the T. 
brucei ICL repair system. (A-C; upper panels). Amplicons (in kbp) corresponding to Tbcsb 
(A & B), Tbexo1 (A & C) or Tbmre11 (B & C) and their hyg-, neo-, pac- or bla-disrupted 
counterparts were generated from template genomic DNAs extracted from the various T. brucei 
lines indicated. (A-C; lower panels). Amplicons (in bp) corresponding to intact Tbcsb (A & 
B), Tbexo1 (A & C) or Tbmre11 (B & C) were generated from template cDNAs derived from 
total RNA extracted from the various T. brucei lines indicated. The integrity of cDNAs (and 
hence RNAs) was evaluated by amplification of a 108 bp control fragment, Tbtert. The primer 
sequences and combinations used in for each amplification are listed in Tables S2 and S3, 
respectively. (D-F). Dose response curves and EC50 values (in µM) of T. brucei lines towards 
mechlorethamine are shown. All data points are mean values ± standard deviations from 
experiments performed in quadruplicate. The susceptibility of the T. brucei single and double 
null mutant lines against mechlorethamine, as judged by their EC50 values, were compared and 
expressed as a fold difference relative to wild type.
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Figure 6: Overview of the T. brucei ICL REPAIRtoire. In the T. brucei DNA replication-
independent ICL repair network (A), ICLs (red bar) recognised as a result of global genome 
surveillance (TbXPC & TbDDB of GG-NER [45] or stalling of transcription complexes 
(TbCSB of TC-NER) triggers NER-mediated incision of the DNA backbone, a process that in 
other organisms involves XPF-ERCC1. This generates an ‘unhooked’ crosslinked 
oligonucleotide that undergoes nucleolytic processing (TbSNM1, TbEXO1) resulting in a 
single nucleotide tethered to the complementary strand, and a single stranded gap. Replication 
protein A binds to the single stranded DNA gap, promotes activation of PCNA that in turn 
recruits error free or error prone TLS DNA polymerases which synthesise new DNA (in purple) 
opposite the unhooked lesion, with the DNA backbone re-joined by DNA ligase: As 
trypanosomes express multiple TLS DNA polymerases the role of one enzyme in ICL repair 
(e.g. TbREV3) could be complemented by other related activities. A second round of NER-
mediated incision of the DNA backbone at sites flanking the ‘unhooked’ crosslinked single 
nucleotide followed by TLS results in complete removal of the covalent linkage and restoration 
of dsDNA. In the T. brucei DNA replication-dependent ICL repair network (B), two DNA 
replication forks converge upon an ICL, causing collapse of each complex. Following 
recognition (trypanosomal mechanism unknown), incision of the DNA backbone occurs, 
possibly through the activity of XPF-ERCC1, MUS18 or FAN1 endonucleases, resulting in 
double strand DNA break (DSB) formation (detected by TbMRE11-mediated formation of 
γH2A), unhooking of the ICL and generation of a single stranded gap: In an SNM1-
independent mechanism, and distinct from the situation observed in mammalian cells [33], the 
unhooked ICL may undergo nucleolytic processing (TbEXO1). A first round of TLS activity 
results in filling of the single stranded gap associated with formation of the ‘unhooked’ 
sequence followed by a second round of NER-mediated incision that removes the ICL from 
the genome, and TLS that restores the dsDNA structure. The DSBs are then repaired by HR 
(involving TbRAD51 and TbBRCA2) using the newly formed dsDNA as template. Activities 
that have been shown to be involved in ICL repair are highlighted in black (XPC, DDB1, 
SNM1, EXO1, MRE11, RAD51 and BRCA2) or white (CSB) whereas activities that are 
hypothesised to function in these systems (XPF-ERCC1, XPG, MUS81, FAN1, TLS Pols & 
ligase) are in grey.
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Figure S1: Gene disruption vectors: Construction and their effects on the T. brucei 
genome. (A). Sequences corresponding to 5′ and 3’ untranslated (UTR) or coding (CDS) 
regions of the target gene were amplified using the specified primer combinations (see Table 
S3) from T. brucei genomic DNA. The resultant fragments (sizes in bp) were sequentially 
cloned either side of a resistance cassette that includes a gene encoding for a T. brucei 
selectable marker (hygromycin B phosphotransferase, neomycin phosphotransferase, 
blasticidin-S-deaminase or puromycin N-acetyltransferase) plus the T. brucei βα or αβ tubulin 
intergenic repeats (tub IR) required for processing the mRNAs (hatched boxes). The restriction 
sites used to remove the T. brucei integration cassette from the plasmid backbone are noted. 
(B-G). Schematic representations of the Tbcsb (B), Tbexo1 (C), Tbmre11 (D), Tbsnm1 (E), 
Tbrad5 (F) and Tbrev3 (G) alleles and the effects of their disruption with DNA fragments 
containing sequences encoding for neomycin phosphotransferase (neo), hygromycin B 
phosphotransferase (hyg), blasticidin-S-deaminase (bla) or puromycin N-acetyltransferase 
(pac), plus the T. brucei tubulin intergenic elements required for processing their mRNAs 
(hatched boxes). In each panel, P1 and P2 (in black) correspond to the primers used to generate 
gene specific amplicons from genomic DNA templates while P3, P4, P5 and P6 correspond to 
neo, hyg, bla and pac specific primers, respectively: The size of the predicted amplicons, 
denoted by a dashed line (in kb) is given. P2 and P7 (in grey) correspond to the primers used 
to generate gene specific amplicons from cDNA templates: The size of the predicted amplicons 
(in bp) is given. The primer sequences and combinations used for each amplification are listed 
in Supplementary Tables S2 and S3, respectively.
Figure S2. Phenotypic analysis of T. brucei null mutants. (A). The cumulative cell density 
of T. brucei Tbexo1Δ, Tbmre11Δ, TbcsbΔ, Tbrad5Δ and Tbrev3Δ (dashed line) cultures was 
followed for 8 days and compared against wild type T. brucei (solid line) cultures grown in 
parallel. Each data point represents the mean cell density ± standard deviation from three 
independent cultures. (B). Cell cycle analysis of T. brucei null mutants. The ratio of DAPI-
stain kinetoplast (K) and one nuclear (N) genomes in one trypanosomes represents a frequently 
used marker for the T. brucei cell cycle. Phase and DAPI images show cells with a 1K1N, 
2K1N and 2K2N arrangement which is indicative of the G1/S, G2/M and post M stages, 
respectively. The growth shows the relative number of nuclear and mitochondrial genomes 
structures from asynchronous cultures of wild type, Tbmre11Δ Tbsnm1Δ and TbcsbΔ parasites. 
The number of cells analysed per cell line is given above each bar. (C). The susceptibility of 
T. brucei wild type (solid line) and Tbmre11Δ (dotted line) to hydroxyurea, UV, phleomycin 
and MMS was assessed. All data points are mean values ± standard deviations from 
experiments performed in quadruplicate. (D). The susceptibility of T. brucei wild type and the 
various null mutant lines against hydroxyurea (HU), phleomycin (Phleo), methyl 
methanesulfonate (MMS) and ultraviolet radiation (UV), as judged by their EC50 values, was 
compared and expressed as a fold difference.
Figure S3. Susceptibility of T. brucei null mutants towards DFMO. Dose response curves 
and EC50 values (in µM) of T. brucei wild type (solid line) and Tbsnm1Δ (A), Tbexo1Δ (B), 
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Tbmre11Δ (C), TbcsbΔ (D), Tbrad5Δ (E) and Tbrev3Δ (F) (dotted line) to DFMO. All data 
points are mean values ± standard deviations from experiments performed in quadruplicate.
Figure S4. Susceptibility of T. brucei Tbrad51 and Tbbrca2 null mutants towards 
mechlorethamine. Dose response curves (A). and EC50 values (in µM) (B) of T. brucei wild 
type (), Tbrad51Δ (▲) and Tbbrca2 Δ () towards mechlorethamine. All data points are 
mean values ± standard deviations from experiments performed in quadruplicate. (C). The 
susceptibility of the T. brucei single and double null mutant lines against mechlorethamine, as 
judged by their EC50 values, were compared and expressed as a fold difference relative to wild 
type.
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Table S1. T. brucei lines used in this project. All null lines are based on the T. brucei MITat 
427 (clone 221a) line. ble, bla, hyg, neo and pac correspond to the genes that encode for the 
selectable markers bleomycin phosphotransferase, blasticidin-S-deaminase, hygromycin B 
phosphotransferase, neomycin phosphotransferase and puromycin N-acetyltransferase, 
respectively.
Cell line genotype
MITat 427 (clone 221a)1
Tbrad51Δ2 Tbrad51::ble/pac
Tbbrca2Δ3 Tbbrca2::bla/pac
Tbsnm1Δ4 Tbsnm1::bla/pac
Tbmre11Δ5 Tbmre11::hyg/neo
TbcsbΔ5 Tbcsb::hyg/neo
Tbexo1Δ5 Tbexo1::hyg/neo
Tbrad5Δ5 Tbrad5::hyg/neo
Tbrev3Δ5 Tbrev3::hyg/neo
Tbsnm1ΔTbmre11Δ5 Tbsnm1::bla/pac; Tbmre11::hyg/neo
Tbsnm1ΔTbcsbΔ5 Tbsnm1::bla/pac; Tbcsb::hyg/neo
Tbsnm1ΔTbexo1Δ5 Tbsnm1::bla/pac; Tbexo1::hyg/neo
Tbsnm1ΔTbrad5Δ5 Tbsnm1::bla/pac; Tbrad5::hyg/neo
Tbsnm1ΔTbrev3Δ5 Tbsnm1::bla/pac; Tbrev3::hyg/neo
TbcsbΔTbmre11Δ5 Tbcsb::hyg/neo; Tbmre11::pac/bla
Tbexo1ΔTbmre11Δ5 Tbexo1::hyg/neo; Tbmre11::pac/bla
TbcsbΔTbexo1Δ5 Tbcsb::hyg/neo; Tbexo1::pac/bla
1Prof G.A.M. Cross, The Rockefeller University.
2Hartley, C.L. and McCulloch, R. (2008) Trypanosoma brucei BRCA2 acts in antigenic 
variation and has undergone a recent expansion in BRC repeat number that is important 
during homologous recombination. Mol Microbiol, 68, 1237-1251.
3McCulloch, R. and Barry, J.D. (1999) A role for RAD51 and homologous recombination in 
Trypanosoma brucei antigenic variation. Genes Dev, 13, 2875-2888.
4Sullivan, J.A., Tong, J.L., Wong, M., Kumar, A., Sarkar, H., Ali, S., Hussein, I., Zaman, I., 
Meredith, E.L., Helsby, N.A. et al. (2015) Unravelling the role of SNM1 in the DNA 
repair system of Trypanosoma brucei. Mol Microbiol, 96, 827-838.
5This study
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Table S2. Primers used in this study. The bases in uppercase correspond to regions of 
homology present in the target DNA, lowercase italics correspond to restriction sites 
incorporated into the primers to facilitate cloning while lowercase non-italics represents a 
nucleotide clamp that aids in the binding of the named restriction enzymes.
Primer name Primer sequence
Tbcsb-KO1 ggggagctcccgcggTCACTTCTGAAGCCAATGTA (SacI/SacII)
Tbcsb-KO2 gggtctagaCACTTTAACTACGATAATGACGCTAA (XbaI)
Tbcsb-KO3 aaagggcccGAGGGATCGTAAAGTGACCTT (ApaI)
Tbcsb-KO4 aaaggtaccCAATTCTATAGCTAACAGCAG (KpnI)
Tbcsb-q1 GGTCTAGCAGCGTTAGAAGCT
Tbcsb-q2 CGCTACCCTCTGTCTTCACTT
Tbmre11-KO1 ggggagctcccgcggTTCAAGTTCCTTGTGACTTC(SacI/SacII)
Tbmre11-KO2 gggtctagaTTGTTTCGTAAATGCCACACT (XbaI)
Tbmre11-KO3 aaagggcccTGCGAACTGTTGAGTAAATGC (ApaI)
Tbmre11-KO4 aaaggtaccCTAATAGTTATCTGGCATGCC (KpnI)
Tbmre11-q1 GGGTTTGACATCATTCAGCCG
Tbmre11-q2 CCGGACGACAGGACGAATACT
Tbexo1-KO1 ggggagctcccgcggATGGGGATTAAAGGGTTATGG(SacI/SacII)
Tbexo1-KO2 gggtctagaCTCCGTTATTACCGCGTCCAC (XbaI)
Tbexo1-KO3 aaagggcccGCTGACCGTGCCAGCGTGCAA (ApaI)
Tbexo1-KO4 aaaggtaccCTACCGTCGCGTATAAGATA’ (KpnI)
Tbexo1-q1 TCGGTGCCGGATGTCATTCGG
Tbexo1-q2 CAACGCACGTTTCACCGGGTC
Tbrad5-KO1 aaagagctcccgcggATGCCACCGAGGAAGAGAAG (SacI/SacII)
Tbrad5-KO2 aaatctagaGTCAAATCCAACGCACGGCAA (XbaI)
Tbrad5-KO3 aaagggcccTTTCAAACGAAACTACCGCCC (ApaI)
Tbrad5-KO4 aaaggtaccTCACGCTTGTTGCGCTTGAAG (KpnI)
Tbrad5-q1 TGGGCGGAAGACAGTTCCAAA
Tbrad5-q2 AAAGGACGCGGTGGAAGAGGA
Tbrev3-KO1 aaagagctcccgcggATGAACTTGTACGTAGTCTC (SacI/SacII)
Tbrev3-KO2 aaatctagaAGTGCCTCCATAGCAACCGAC (XbaI)
Tbrev3-KO3 aaagggcccCATTGTTCCTACGCTCGACAG (ApaI)
Tbrev3-KO4 aaaggtaccTCAGCGAGTCGTTACGTAGTC (KpnI)
Tbrev3-q1 CGTCGGCGTTACACAACAATT
Tbrev3-q2 CACTAGGGGGTCCTGTGATGT
Tbsnm1-KO1 aaagagctcccgcggGCAGGTGGAGCTGCAGGTAAG
Tbsnm1-seq1 CACCAGATCACCATTGCGGAG
Tbsnm1-q1 AGATGCTAAACAAGAAGAGTC
Tbtert-F AGGAACTGTCACGGAGTTTGC
Tbtert-R GAGCGTGTGACTTCCGAAGG 
Neo TCAGAAGAACTCGTCAAGAAG
Hyg CTATTCCTTTGCCCTCGGACG 
Pac CGGGCTTGCGGGTCATGCACCA 
Bla GGATTCTTCTTGAGACAAAGGCTT
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Supplementary Table S3. Primers: Function and combinations 
Gene Function Primer combination
Tbmre11 Gene disruption vector: 
  5’ targeting fragment
  3’ targeting fragment
Tbmre11-KO1 + Tbmre11-KO2
Tbmre11-KO3 + Tbmre11-KO4
Null mutant validation (gDNA):
  Tbmre11 allele
  hyg-interrupted Tbmre11 allele
  neo-interrupted Tbmre11 allele
  pac-interrupted Tbmre11 allele
  bla-interrupted Tbmre11 allele
Tbmre11-KO1 + Tbmre11-q2
Tbmre11-KO1 + Hyg
Tbmre11-KO1 + Neo
Tbmre11-KO1 + Pac
Tbmre11-KO1 + Bla
Null mutant validation (cDNA):
  Tbmre11 mRNA Tbmre11-q1 + Tbmre11-q2
Tbcsb Gene disruption vector: 
  5’ targeting fragment
  3’ targeting fragment
Tbcsb-KO1 + Tbcsb-KO2
Tbcsb-KO3 + Tbcsb-KO4
Null mutant validation (gDNA):
  Tbcsb allele
  hyg-interrupted Tbcsb allele
  neo-interrupted Tbcsb allele
Tbcsb-KO1 + Tbcsb-q2
Tbcsb-KO1 + hyg
Tbcsb-KO1 + neo
Null mutant validation (cDNA):
  Tbcsb mRNA Tbcsb-q1 + Tbcsb-q2
Tbexo1 Gene disruption vector: 
  5’ targeting fragment
  3’ targeting fragment
Tbexo1-KO1 + Tbexo1-KO2
Tbexo1-KO3 + Tbexo1-KO4
Null mutant validation (gDNA):
  Tbexo1 allele
  hyg-interrupted Tbexo1 allele
  neo-interrupted Tbexo1 allele
  pac-interrupted Tbexo1 allele
  bla-interrupted Tbexo1 allele
Tbexo1-KO1 + Tbexo1-q2
Tbexo1-KO1 + Hyg
Tbexo1-KO1 + Neo
Tbexo1-KO1 + Pac
Tbexo1-KO1 + Bla
Null mutant validation (cDNA):
  Tbexo1 mRNA Tbexo1-q1 + Tbexo1-q2
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Gene Function Primer combination
Tbrad5 Gene disruption vector: 
  5’ targeting fragment
  3’ targeting fragment
Tbrad5-KO1 + Tbrad5-KO2
Tbrad5-KO3 + Tbrad5-KO4
Null mutant validation (gDNA):
  Tbrad5 allele
  hyg-interrupted Tbrad5 allele
  neo-interrupted Tbrad5 allele
Tbrad5-KO1 + Tbrad5-q2
Tbrad5-KO1 + Hyg
Tbrad5-KO1 + Neo
Null mutant validation (cDNA):
  Tbrad5 mRNA Tbrad5-q1 + Tbrad5-q2
Tbrev3 Gene disruption vector: 
  5’ targeting fragment
  3’ targeting fragment
Tbrev3-KO1 + Tbrev3-KO2
Tbrev3-KO3 + Tbrev3-KO4
Null mutant validation (gDNA):
  Tbrev3 allele
  hyg-interrupted Tbrev3 allele
  neo-interrupted  Tbrev3 allele
Tbrev3-KO1 + Tbrev3-q2
Tbrev3-KO1 + Hyg
Tbrev3-KO1 + Neo
Null mutant validation (cDNA):
  Tbrev3 mRNA Tbrev3-q1 + Tbrev3-q2
Tbsnm1 Null mutant validation (gDNA):
  Tbsnm1 allele
  pac-interrupted Tbsnm1 allele
  bla-interrupted  Tbsnm1 allele
Null mutant validation (cDNA):
  Tbsnm1 mRNA
Tbsnm1-KO1 + Tbsnm1-seq1
Tbsnm1-KO1 + Pac
Tbsnm1-KO1 + Bla
Tbsnm1-q2 + Tbsnm1-seq1
Tbtert Null mutant validation (cDNA):
  Tbtert mRNA Tbtert-F + Tbtert-R
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Table 1. Susceptibility of T. brucei null lines to DNA damaging treatments. 
Data represents EC50 values of various T. brucei lines against hydroxyurea (HU), phleomycin, methyl methanesulfonate (MMS) and ultraviolet 
light (UV). All values are means ± standard deviations from experiments performed in quadruplicate. The ratio of EC50 values between wild type 
and single/double null mutant lines is shown as fold difference, in parentheses.
T. brucei EC50Treatment
wild type Tbsnm1Δ Tbmre11Δ Tbsnm1ΔTbmre11Δ
Hydroxyurea (μM) 53.37 ± 3.68 40.62 ± 2.26 (1.3) 43.10 ± 0.84 (1.2) 33.77 ± 0.38 (1.6)
Phleomycin (μM) 0.12 ± 0.01 0.12 ± 0.00 (1.0) 0.01 ± 0.00 (12.0) 0.01 ± 0.00 (12.0)
MMS (μM) 33.02 ± 0.28 35.82 ± 0.29 (0.9) 12.63 ± 0.47 (2.5) 15.32 ± 1.32 (2.2)
UV (kJ/cm) 2.58 ± 0.39 2.66 ± 0.18 (1.0) 0.53 ± 0.11 (4.9) 0.11 ± 0.09 (23.3)
wild type Tbsnm1Δ Tbexo1Δ Tbsnm1Δ Tbexo1Δ
Hydroxyurea (μM) 47.56 ± 1.90 38.62 ± 2.71 (1.2) 52.59 ± 1.54 (0.9) 43.59 ± 1.84 (1.1)
Phleomycin (μM) 0.12 ± 0.00 0.12 ± 0.00 (1.0) 0.06 ± 0.00 (2.0) 0.05 ± 0.00 (2.2)
MMS (μM) 27.89 ± 0.63 42.28 ± 2.89 (0.7) 32.46 ± 0.71 (0.9) 40.44 ± 1.32 (0.7)
UV (kJ/cm) 3.54 ± 0.20 3.90 ± 0.32 (0.9) 2.07 ± 0.14 (1.7) 3.15 ± 0.98 (1.1)
wild type Tbsnm1Δ TbcsbΔ Tbsnm1Δ TbcsbΔ
Hydroxyurea (μM) 71.88 ± 0.89 67.91 ± 1.80 (1.1) 69.00 ± 2.67 (1.0) 69.77 ± 2.38 (1.0)
Phleomycin (μM) 0.12 ± 0.01 0.09 ± 0.01 (1.3) 0.12 ± 0.01 (1.1) 0.12 ± 0.01 (1.1)
MMS (μM) 27.78 ± 5.17 30.94 ± 13.45 (0.9) 26.73 ± 8.54 (1.0) 31.22 ± 10.4 (0.9)
UV (kJ/cm) 2.12 ± 0.18 2.47 ± 1.49 (0.9) 0.42 ± 0.14 (5.1) 0.47 ± 0.05 (4.5)
wild type Tbsnm1Δ Tbrad5Δ Tbsnm1Δ Tbrad5Δ
Hydroxyurea (μM) 67.39 ± 0.65 50.21 ± 1.72 (1.3) 58.18 ± 0.39 (1.2) 52.20 ± 1.94 (1.3)
Phleomycin (μM) 0.12 ± 0.01 0.09 ± 0.00 (1.4) 0.08 ± 0.00 (1.5) 0.09 ± 0.00 (1.4)
MMS (μM) 41.41 ± 3.56 45.76 ± 0.65 (0.9) 37.82 ± 1.16 (1.1) 45.97 ± 0.38 (0.9)
UV (kJ/cm) 3.61 ± 0.29 3.17 ± 0.34 (1.1) 3.74 ± 0.94 (1.0) 3.87 ± 0.35 (0.9)
wild type Tbsnm1Δ Tbrev3Δ Tbsnm1Δ Tbrev3Δ
Hydroxyurea (μM) 67.39 ± 0.65 50.21 ± 1.72 (1.3) 50.68 ± 0.83 (1.3) 52.20 ± 1.76 (1.3)
Phleomycin (μM) 0.12 ± 0.01 0.09 ± 0.00 (1.4) 0.09 ± 0.00 (1.4) 0.08 ± 0.00 (1.6)
MMS (μM) 41.41 ± 3.56 45.76 ± 0.65 (0.9) 38.65 ± 1.49 (1.0) 33.88 ± 0.70 (1.2)
UV (kJ/cm) 3.46 ± 0.45 3.92 ± 1.56 (0.9) 3.52 ± 1.08 (1.0) 3.55 ± 0.73 (1.0)
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